Welcome to our dedicated page for Edwards Lifesciences news (Ticker: $EW), a resource for investors and traders seeking the latest updates and insights on Edwards Lifesciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Edwards Lifesciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Edwards Lifesciences's position in the market.
Rhea-AI Summary
Edwards Lifesciences (NYSE: EW) reported strong financial results for the first quarter of 2024, with Q1 sales growing 10% to $1.6 billion. Key highlights include a 6% growth in TAVR sales, a 75% growth in TMTT sales, and an EPS of $0.58. The company raised its 2024 sales guidance, particularly for TMTT and Surgical segments, and remains confident in its innovation-driven strategy. Edwards is on track with its Critical Care spin-off and expects healthy TAVR growth in the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
-
Rhea-AI Summary
Edwards Lifesciences (NYSE: EW) will release its Q1 2024 operating results on April 25, 2024, followed by a conference call to discuss the results. Investors can dial in or access the call through the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
-
Rhea-AI Summary
Edwards Lifesciences (NYSE: EW) releases data from the HUDDLE study, revealing a significant discrepancy in self-awareness of heart disease among NFL Alumni Association members. The study, presented at ACC.24/WCC, highlights a high prevalence of hypertension.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
Rhea-AI Summary
PECA Labs, a medical device company, receives an additional CE Mark for its exGraft family of vascular grafts, allowing for post-operative expansion up to 140 percent. The company also opens a new facility for polymer processing and appoints Jeffrey O’Donnell, Sr. as executive chairman.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
-
Rhea-AI Summary
Edwards Lifesciences (NYSE: EW) presented compelling results from real-world studies at CRT 2024, showcasing excellent outcomes for patients treated with the SAPIEN valve platform. The SAPIEN 3 Ultra RESILIA valve demonstrated lower rates of paravalvular leak, improved gradients, and larger effective orifice areas compared to previous versions. The data were published in JACC: Cardiovascular Interventions, highlighting significant advancements in TAVR technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
-
Rhea-AI Summary
Edwards Lifesciences Corporation (NYSE: EW) will participate in the TD Cowen Healthcare Conference on March 5, 2024. CEO Bernard Zovighian and CFO Scott Ullem will present at 10:30 a.m. ET. A live webcast will be available on the investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
Rhea-AI Summary
Edwards Lifesciences (NYSE: EW) reported Q4 sales growth of 14% to $1.53 billion, 2023 sales of $6.0 billion, and Q4 EPS of $0.61. The company completed enrollment early in PROGRESS pivotal trial, received early FDA approval for EVOQUE, and executed a $400 million accelerated share repurchase in Q4. The company is confident in 2024 guidance of 8 to 10% constant currency sales growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
-
Rhea-AI Summary
Edwards Lifesciences Corporation (NYSE: EW) has received FDA approval for its EVOQUE tricuspid valve replacement system, the first transcatheter therapy for the treatment of tricuspid regurgitation. The system is indicated for patients with symptomatic severe TR despite optimal medical therapy and has shown favorable safety and effectiveness outcomes in a pivotal trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.38%
Tags
-
Rhea-AI Summary
Edwards Lifesciences (NYSE: EW) will announce its Q4 2023 operating results on February 6, 2024, followed by a conference call. The call will be available live and archived on the Investor Relations section of the Edwards website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
Rhea-AI Summary
Edwards Lifesciences Corporation (NYSE: EW) will participate in the J.P. Morgan Healthcare Conference on Jan. 9, 2024. CEO Bernard Zovighian and CFO Scott Ullem will present at 11:15 a.m. PT. A live webcast will be available on the investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
Edwards Lifesciences Corp
NYSE:EW
EW Rankings
EW Stock Data
51.73B
595.33M
0.89%
84.02%
1.73%
Surgical Appliance and Supplies Manufacturing
Manufacturing
United States of America
IRVINE
About EW
edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.